Capecitabine (Xeloda) and irinotecan (CPT-11, Camptosar) both have demonstrated single-agent activity in patients with colorectal cancer.
David J. Kerr, CBE, MD, DSC, FRCP, FMEDSCI
Advertisement
Articles by David J. Kerr, CBE, MD, DSC, FRCP, FMEDSCI
Advertisement
Latest Updated Articles
- Capecitabine/Irinotecan Combination Regimens in Colorectal Cancer
Published: April 1st 2002 | Updated:
Advertisement
Advertisement
Trending on CancerNetwork
1
PEG Hydrogel Reduces Rectal Radiation During Cervical Cancer Therapy
2
Early Detection, Education Are Key to Combat Rising Pancreatic Cancer Cases
3
Sonrotoclax Earns FDA Priority Review in R/R Mantle Cell Lymphoma
4
Examining Developments in Safe Administration of Nuclear Agents
5
